OR WAIT null SECS
Philip Ward is ACT's European editor, phone +44 1244 538583, firstname.lastname@example.org
Françoise Meunier will become Director of Special Projects for the European Organization for Research and Treatment of Cancer starting April 1, 2015.
After 24 years of working as Director General of the European Organization for Research and Treatment of Cancer (EORTC), Françoise Meunier will move to a new role within the Brussels-based operation. She will become Director of Special Projects from April 1, 2015.
EORTC has announced that a plenary session in honor of Meunier’s achievements will take place at the Crowne Plaza Brussels-Le Palace in Belgium on March 12, 2015 at 4:00pm local time. The event is designed to recognize her major commitment to the management of pan-European cancer research.
As Director General, Meunier has been involved in the coordination and administration of all activities in order to promote EORTC as a major European research organization. She has been responsible for the organization of scientific activities, public relations and medium-term strategies as defined by the EORTC Board as well as for internal and external the communication.
Before joining EORTC in 1991, Meunier was Head of the Infectious Diseases Department at Institute Jules Bordet in Brussels, Belgium, and her personal area of research included the management of infections in patients with Cancer and mainly Invasive Fungal Infections. She was awarded the Belgian Laureate “Prix Femmes d’Europe 2004-2005”, and in 2007 she was conferred the title of Baroness by King Albert II of Belgium. Two years later she received the Pezcoller Foundation award for her contribution to oncology, and she became a fellow of the European Academy of Cancer Sciences in 2011 and a member of the IMI (Innovative Medicine Initiative) Scientific Committee of the European Union in 2012. In 2014, she was appointed council member of the FEAM (Federation of European Academy of Medicine).
The EORTC is an independent research organization dedicated to investigator driven clinical trials and translational research. Consisting of both a network and a coordinating scientific and operational infrastructure, it seeks to not only establish ‘state-of-the-art’ treatments but also ensure that new cancer agents are developed and tested efficiently with the aim of minimizing delays between laboratory discovery and their therapeutic benefit for patients.
Read the full release here.